Fulgent Genetics (FLGT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$323.9M

Revenue (quarter)

$85.4M

Revenue growth (year over year)

+4.38%

Gross profit (trailing twelve months)

$115.3M

Gross margin

35.58%

Net income (trailing twelve months)

−$85.5M

Net income (quarter)

−$29.7M

Net income growth (year over year)

−54.34%

Net margin

−26.38%

Return on equity

−7.97%

EPS (trailing twelve months)

−$2.83

Book value per share

$36.40

P/E (trailing twelve months)

—

Price to book

0.58

Debt to assets

8.56%

Payout ratio

—

Dividend yield

—

Company profile

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

• Is Fulgent Genetics (FLGT) profitable?

  No. Fulgent Genetics reported a net loss of $85.5M over the trailing twelve months.

• How much revenue does Fulgent Genetics (FLGT) make?

  Fulgent Genetics generated $323.9M in revenue over the trailing twelve months, up 4.38% year over year.

• How do I buy stock in Fulgent Genetics (FLGT)?

  FLGT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.